Tackling non-communicable diseases in low- and middle-income countries: is the evidence from high-income countries all we need? by Ebrahim, Shah et al.
Bartlett, C; Hooper, L; Ebrahim, S (2001) Dietary sodium and blood
pressure. The New England journal of medicine, 344 (22). 1717-8;
author reply 1718-9. ISSN 0028-4793
Downloaded from: http://researchonline.lshtm.ac.uk/12624/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
 INSTRUCTIONS FOR LETTERS TO THE EDITOR
 
Letters to the Editor are considered for publication (subject to editing and abridgment) provided they do not contain material that has been 
submitted or published elsewhere. Please note the following: •Your letter must be typewritten and triple-spaced. •Its text, not including 
references, must not exceed 250 words if it is in reference to a recent 
 
Journal
 
 article, or 400 words in all other cases (please provide a word 
count). •It must have no more than five references and one figure or table. •It must not be signed by any more than three authors. •Letters 
referring to a recent 
 
Journal
 
 article must be received within four weeks of its publication. •Please include your full address, telephone number, 
fax number, and e-mail address. •You may send us your letter by standard mail, fax, or e-mail. 
Our address: 
 
Letters to the Editor 
 
•
 
New England Journal of Medicine
 
 
 
•
 
10 Shattuck St.
 
•
 
 Boston, MA 02115
 
Our fax numbers: 
 
617-739-9864
 
 and 
 
617-734-4457
 
Our e-mail address: 
 
letters@nejm.org
 
We cannot acknowledge receipt of your letter, but we will notify you when we have made a decision about publication. We are unable to 
provide prepublication proofs. Financial associations or other possible conflicts of interest must be disclosed. Submission of a letter constitutes 
permission for the Massachusetts Medical Society, its licensees, and its assignees to use it in the 
 
Journal’
 
s various print and electronic 
publications and in collections, revisions, and any other form or medium.
 
1716
 
·
 
N Engl J Med, Vol. 344, No. 22
 
·
 
May 31, 2001
 
·
 
www.nejm.org
 
The New England Journal  of  Medicine
 
Correspondence
 
Dietary Sodium and Blood Pressure
 
To the Editor:
 
 The DASH–Sodium Trial (Jan. 4 issue)
 
1
 
has demonstrated that a reduction in sodium intake over
a period of 30 days lowers blood pressure. This finding is
consistent with what more than 100 previous short-term,
randomized trials have convincingly shown. What is remark-
able — and disappointing, given this demanding and cost-
ly undertaking — is that the report was limited to the sin-
gle selected favorable effect of salt on blood pressure, to
the exclusion of other important physiological effects. For
example, reducing the consumption of sodium also increas-
es the plasma renin level by a factor of 3.6 and the aldos-
terone level by a factor of 3.2 — effects proportional to
the degree of sodium reduction.
 
2
 
The relation between sodium intake and all physiological
phenomena is of great scientific interest. By contrast, pa-
tients, physicians, and public health advocates need to know
how salt intake affects the quality and duration of life. The
scanty published data available are not encouraging to those
who preach salt restraint. An exception is the finding in a
subgroup of obese subjects (28 percent) in the National
Health and Nutrition Examination Survey Epidemiologic
Follow-up Study of a direct relation between salt intake
and cardiovascular outcome. No such relation appeared in
the nonobese majority (72 percent).
 
3
 
 Moreover, in the en-
tire survey population, there was an inverse relation between
sodium intake and cardiovascular morbidity.
 
4
 
Perhaps in some people the hemodynamic benefits of
salt restriction will outweigh its hormonal and metabolic
hazards. However, at this point, in the absence of strong
evidence of a consistent health effect, a single universal rec-
ommendation for a reduction in dietary sodium reflects
faith more than science.
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To the Editor: 
 
Sacks et al. concluded that their results in
the DASH–Sodium Trial “provide support for a more ag-
gressive target for reduced sodium intake, in combination
with the use of the DASH (Dietary Approaches to Stop Hy-
pertension) diet, for the prevention and treatment of ele-
vated blood-pressure levels.” That conclusion is misleading
at best.
Given the characteristics of the study cohort, which are
greatly skewed toward the expression of salt sensitivity, the
failure to provide the 
 
Journal
 
’s readers with all the avail-
able data must be addressed. Even the very limited data pro-
vided in Figures 1 and 2 of the article indicate that from
the standpoint of clinical application, any effect of salt re-
striction on blood pressure was limited to black women with
hypertension. Thus, the authors’ statement that these find-
ings are broadly applicable to the entire population is not
true. To prove otherwise, the authors are obligated to report,
in a format similar to that of Figure 1, the analyses of sub-
groups defined according to race, presence or absence of
hypertension, sex, age, and body-mass index.
Those data are necessary to document the principal find-
ing of the study: for the vast majority of people, overall
dietary improvements eliminate the effects of salt on blood
pressure. Earlier reports
 
1,2
 
 that adequate mineral intake from
dairy products, fruits, and vegetables is far more important
than salt in determining blood pressure have been con-
firmed by this study. If the authors had provided graphs
that told the whole story, that conclusion would have been
readily apparent.
Unfortunately, as currently presented, these data only
provide further justification to the 70 percent of recently
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surveyed Americans who said they do not trust the gov-
ernment’s dietary recommendations.
 
3
 
 As others have put it,
the salt-restriction advocates want to protect the public not
only from salt but also from the data.
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To the Editor: 
 
The continuing controversy about general
advice to reduce dietary sodium has arisen in part because
the effect of sodium may be limited to subgroups of the
population who are salt-sensitive. In their discussion of the
effect of sodium reduction in persons without hyperten-
sion, Sacks et al. highlight the reductions in systolic blood
pressure that occurred in subjects on the control diet. Figure
2 of the article shows that the reduction in sodium intake
in subjects on the DASH diet had a significant effect on
systolic blood pressure in persons without hypertension only
if they were black and only when they switched from the
high-sodium to the low-sodium diet.
The risk of coronary disease increases as the diastolic
blood pressure increases within quintiles of systolic blood
pressure.
 
1
 
 A meta-analysis of observational studies of blood
pressure, stroke, and coronary disease
 
2
 
 presents data accord-
ing to diastolic but not systolic blood pressure. A meta-
analysis of randomized trials of antihypertensive-drug ther-
apy shows a reduction in the risks of stroke and coronary
heart disease in relation to reductions in diastolic but not
systolic blood pressure.
 
3
 
 To arrive at the best estimates of
the expected reductions in disease events that would result
from changes in the diets of various subgroups — especially
persons without hypertension — information is required
about the effect on diastolic blood pressure of lowering di-
etary sodium in the DASH and control diets for subgroups
defined by ethnic background, presence or absence of hy-
pertension, and sex.
The most recent meta-analysis of clinical trials of sodium
reduction reported no significant effect of sodium reduc-
tion on diastolic blood pressure in persons without hyper-
tension.
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To the Editor: 
 
In their report of the 90-day DASH–
Sodium Trial, Sacks et al. do not set their findings in the
context of longer-term trials in which sodium intake has
been manipulated to reduce blood pressure. We have iden-
 
*For the first three trials, the net mean change in systolic blood pressure was calculated by sub-
tracting the mean change in the control group from the mean change in the experimental group. For
the DASH–Sodium Trial, the data presented represent the mean change for the 204 participants in
the control group from the high-sodium phase to the low-sodium phase of the control diet. CI de-
notes confidence interval, HPT Hypertension Prevention Trial, TOHP Trial of Hypertension Preven-
tion, and DASH Dietary Approaches to Stop Hypertension. In the 1998 Trial of Nonpharmacologic
Interventions in the Elderly, involving 681 subjects, the hazard ratios for the composite end point of
hypertension, restarting medication, or a cardiovascular event by 30 months (in the sodium-reduction
group vs. the control group) were 0.60 (95 percent confidence interval, 0.45 to 0.80) in obese sub-
jects and 0.75 (95 percent confidence interval, 0.59 to 0.95) in nonobese subjects.
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HPT, 1990 392 6 ¡1.7 (¡3.4 to 0.0) 36 +0.1 (¡1.8 to +2.0)
TOHP-I, 1992 744 12 ¡1.9 (¡3.0 to ¡0.8) 18 ¡1.7 (¡2.9 to ¡0.6)
TOHP-II, 1997 1190 6 ¡2.9 (¡3.9 to ¡1.9) 36 ¡1.0 (¡2.0 to 0.0)
DASH–Sodium, 2000 204 1 ¡6.7 (¡5.4 to ¡8.0) — —
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tified 10 randomized, controlled trials that lasted six months
or longer. Four trials, all conducted in the United States,
were similar in size to the DASH–Sodium Trial, having at
least 200 participants (Table 1, previous page).
In three of these trials, involving adults not receiving med-
ication who had high-normal blood pressure,
 
1-3
 
 the differ-
ence between the mean reduction in systolic blood pressure
in the experimental group and that in the control group was
modest after 6 months of intervention and became mini-
mal after 12 months. In the fourth trial, the Trial of Non-
pharmacologic Interventions in the Elderly,
 
4
 
 however, there
was observable but limited success in weaning seniors off
antihypertensive medication by means of a low-sodium diet.
In all four trials, there was difficulty in maintaining so-
dium reduction at the targeted level over the long term,
even though the interventions were intensive. This may ex-
plain the minimal efficacy, although an alternative hypothesis
is that baroreceptor and renal homeostasis through renin–
angiotensin mechanisms restored blood pressure to its pre-
intervention level, despite the reduction in sodium.
 
5
 
 Thus,
it is improbable that the reductions in blood pressure as-
cribed by Sacks and colleagues to the manipulation of so-
dium intake (as distinct from the reductions that were due
to the DASH diet) could be sustained over the long term in
adults not receiving medication, either in a clinical situation
or in the general population. Nevertheless, the issue of
whether low sodium intake from childhood promotes life-
long normotension remains to be resolved.
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The authors reply:
 
To the Editor: 
 
The contribution of the DASH–Sodium
Trial to the salt issue is data on the magnitude of the re-
duction in blood pressure related to a reduction in sodium.
In our view, the magnitude is greater in the DASH–Sodium
feeding study than has been reported in meta-analyses be-
cause people have serious difficulty finding enough low-
sodium foods to enable them to adhere fully to reduced-
sodium diets. We hope that the food industry will respond
to the DASH–Sodium findings as a business opportunity.
We are surprised by Alderman’s assertion that reduced
sodium intake, especially to 65 mmol per day, is harmful.
Reduced sodium does raise the plasma renin level, but so
does diuretic therapy, which prevents cardiovascular disease.
Moreover, in a large sample of the general population, the
plasma renin level was not associated with cardiovascular dis-
ease.
 
1
 
 Experience with antihypertensive drugs shows that
any reduction in blood pressure reduces cardiovascular dis-
ease. Mortality trials are not required for drug approval.
Should sodium reduction be different? Finally, the epide-
miologic study by Alderman et al.
 
2
 
 shows an increase in the
rate of death from cardiovascular disease with higher salt
intake when the analysis is appropriately adjusted for the
total caloric intake of the subjects.
We assure McCarron and readers that the DASH–Sodium
findings are qualitatively the same among all subgroups but
differ quantitatively, as we showed in representative exam-
ples. We plan to publish the full subgroup results soon.
The substantial reductions in blood pressure give additional
strength to the long-standing dietary guidelines of public
and private health organizations.
Petitti and Freedman focus on a subgroup effect that did
not attain statistical significance, while ignoring the consis-
tency of the direction of the results for all subgroups, which
vary only in magnitude. Moreover, a substantial proportion
of white and normotensive persons are indeed sensitive to
salt.
 
3
 
 Systolic blood pressure was prespecified as the trial’s
primary outcome because it is more closely linked than di-
astolic blood pressure to cardiovascular disease.
 
4
 
We agree with the view of Bartlett et al. that difficulty in
achieving long-term adherence to low-sodium diets limits
the long-term reduction in blood pressure. In the outstand-
ing trial of MacGregor et al.,
 
5
 
 the reduction of sodium in-
take from 200 to 50 mmol per day in a highly motivated
group of subjects with hypertension reduced systolic blood
pressure by 18 mm Hg after one year — the same as the
reduction after one month. There is no indication in the
literature of an adaptation effect.
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A Pneumococcal Conjugate Vaccine and Acute 
Otitis Media
To the Editor: In the report by Eskola et al. (Feb. 8 is-
sue)1 of the efficacy of a pneumococcal conjugate vaccine
against otitis media, the data argue strongly against their
conclusion that “the effect of the pneumococcal conjugate
vaccine can be substantial.” In the case of 94 percent of
those immunized with the pneumococcal conjugate vaccine,
otitis media would not have been prevented. The study
also substantiates one of the greatest feared limits of the
heptavalent pneumococcal conjugate vaccine — that the
frequency of disease would remain the same as a result of
increases in the rates of infection with all the pneumococ-
cal serotypes that were not included in the vaccine (a phe-
nomenon sometimes referred to as serotype replacement).
The data of Eskola et al. demonstrate a 33 percent increase
in the incidence of otitis media from pneumococcal sero-
types that were not included in the vaccine.
ARTHUR LAVIN, M.D.
Pediatric Partners of Cleveland
Beachwood, OH 44122-5416
1. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate 
vaccine against acute otitis media. N Engl J Med 2001;344:403-9.
To the Editor: Eskola et al. state that “up to 1.2 million
of the 20 million yearly episodes of acute otitis media in
the United States could theoretically be prevented if the
[pneumococcal conjugate] vaccine were widely used.” This
theoretical benefit must not be used as an official justifi-
cation for vaccination. 
The vaccine was officially recommended for use in all
children on the basis of its efficacy against invasive diseas-
es.1 The reported relative reduction in the risk of episodes of
6 percent achieved by vaccination still leaves the total risk
high enough for many immunized children to have acute oti-
tis media. This factor could lessen the credibility of the rec-
ommendation for vaccination.
A more powerful trial2 reported a reduction in acute
otitis media of up to 22.8 percent in one subgroup of chil-
dren with frequent episodes. Since 14 percent of children
account for approximately 50 percent of the episodes of
acute otitis media, the number of episodes could be signif-
icantly reduced by the selection of appropriate candidates
for immunization. In countries that will not adopt the U.S.
recommendation, selective vaccination of high-risk sub-
groups is a better way to keep the public trust.
YISHAY OFRAN, M.D.
Hebrew University
Jerusalem 91240, Israel
ARIELLA OFRAN, M.D.
Maccabi Healthcare Services
Tel Aviv 68125, Israel
1. Committee on Infectious Diseases. Recommended childhood immuni-
zation schedule: United States, January-December 2001. Pediatrics 2001;
107:202-4.
2. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunoge-
nicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr 
Infect Dis J 2000;19:187-95.
To the Editor: Given the poor overall efficacy of the
pneumococcal conjugate vaccine in the study by Eskola et
al., the authors’ conclusions are a bit too optimistic. Accord-
ing to the protocol, all infants received four vaccinations,
which were certainly not painless and which led to the pre-
vention of only 6 percent of all cases of acute otitis media.
For the moment, more could be gained by changing
our attitude toward acute otitis media. In the Netherlands,
acute otitis media is seen as a self-limiting disease. Often,
parents do not take their children to the doctor for this
common childhood disease. The efficacy of antibiotics for
this disease is moderate,1 even in the youngest children.2
Educating doctors and parents about acute otitis media
will lead to a decrease in antibiotic prescriptions for this
illness, as has been shown in a recent trial.3
ROGER A.M.J. DAMOISEAUX, M.D., PH.D.
Flessenbergerweg 5
8191 LH Wapenveld, the Netherlands
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314:1526-9.
2. Damoiseaux RAMJ, van Balen FAM, Hoes AW, Verheij TJ, de Melker 
RA. Primary care based randomised, double blind trial of amoxicillin ver-
sus placebo for acute otitis media in children aged under 2 years. BMJ 
2000;320:350-4.
3. Little P, Gould C, Williamson I, Moore M, Warner G, Dunleavy J. 
Pragmatic randomised controlled trial of two prescribing strategies for 
childhood acute otitis media. BMJ 2001;322:336-42.
To the Editor: The vaccine manufacturer’s vice president
and contractors conclude that the new pneumococcal vac-
cine is “efficacious in the prevention of acute otitis me-
dia.” Given the 95 percent confidence interval of –4 to 16
percent, the data presented by Eskola et al. do not support
this conclusion. As the authors admit, “the negative number
indicates” that the treated group could have had more ep-
isodes than the controls. These same data — 1251 episodes
in the vaccine group as compared with 1345 episodes in
the control group, a clinically and statistically insignificant
difference in the rate of 3.6 percent (absolute benefit) —
were presented to an advisory committee of the Food and
Drug Administration (FDA) in November 1999. Therefore,
the FDA rejected the use of this vaccine for otitis media.
Moreover, the authors’ use of the number of episodes in-
stead of the number of patients as the experimental unit is
incorrect because it inflates the outcome.
The most interesting results concern the pneumococcal
ecology. In a short time span, the predicted serotype replace-
ment1 (also observed with other bacterial vaccines2-4) was
realized. Eskola et al. report that the “number of episodes
due to all other [pneumococcal] serotypes increased by 33
percent.” With this clear warning sign, it is a perilous ex-
periment in microbial ecology to push the use of the hep-
tavalent pneumococcal vaccine.
ERDEM I. CANTEKIN, PH.D.
University of Pittsburgh School of Medicine
Pittsburgh, PA 15213
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2001 Massachusetts Medical Society. All rights reserved. 
1720 · N Engl J Med, Vol. 344, No. 22 · May 31, 2001 · www.nejm.org
The New England Journal  of  Medicine
1. Spratt BG, Greenwood BM. Prevention of pneumococcal disease by 
vaccination: does serotype replacement matter? Lancet 2000;356:1210-1.
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To the Editor: As a general pediatrician, I think we must
proceed with caution when relaying the data of Eskola et
al. to our patients’ parents. Although the vaccine reduced
the incidence of acute otitis media caused by pneumococcus,
especially by the strains included in the vaccine, the overall
reduction in cases of acute otitis media was only 6 percent.
The clinical significance of this finding is questionable.
I have already had several parents ask me why their child
had an ear infection after having received the “ear-infec-
tion vaccine.” At a time when many parents are already sus-
picious of the reported safety and efficacy of vaccines, un-
realistic expectations may hinder the use of this vaccine and
therefore limit the documented protection it affords against
invasive pneumococcal disease.1
KURTIS L. SAUDER, M.D.
Blue Ridge Pediatrics
Staunton, VA 24402-2665
1. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunoge-
nicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr 
Infect Dis J 2000;19:187-95.
The authors reply:
To the Editor: It is important to make a distinction be-
tween the effect of the pneumococcal conjugate vaccine on
a larger population and the expected benefits in an individ-
ual child. Even though the proportion of vaccine-prevent-
able episodes of otitis media is small, the absolute number
of potentially preventable attacks at the population level is
considerable, because otitis media is such a common dis-
ease. The impact on otitis media has been estimated to ac-
count for 60 percent of the cost savings expected from the
prevention of pneumococcal disease through a vaccination
program.1 Thus, our conclusion that the effect of the pneu-
mococcal conjugate vaccine on otitis media could be sub-
stantial is correct and is an important message to policy-
makers who are deciding whether the vaccine should be
included in national immunization programs. However, we
fully agree that the information given to parents should fo-
cus on protection provided by the vaccine against invasive
pneumococcal disease. Furthermore, the suggestion of tar-
geting the vaccine to selected otitis-prone groups would
be difficult to implement and would obscure the primary
objective of preventing invasive disease.
We cannot agree with Dr. Cantekin that using the num-
ber of episodes instead of the number of children as exper-
imental units is incorrect. The tendency to recurrence is
characteristic of acute otitis media. A vaccine that does not
afford protection against recurrent attacks would be of little
value. We therefore purposely calculated the efficacy of the
vaccine against all episodes of otitis media, not just the
first ones (i.e., counting only one episode per child). This
approach did not inflate the outcome, as shown by the effi-
cacy rates against first as compared with all episodes of oti-
tis media (52 percent vs. 57 percent for infections caused by
serotypes included in the vaccine and 12 percent vs. 6 per-
cent for episodes from any cause). The reduction of 12
percent is statistically significant (95 percent confidence
interval, 1 to 22 percent).
We share the concern about the increase in otitis media
caused by the serotypes that were not included in the vac-
cine among those who received the conjugate vaccine. How-
ever, we find it reassuring that after several years of follow-
up, no indication of serotype replacement has been observed
in invasive disease among the participants of the California
trial.2,3 The long-term effects of serotype replacement re-
main unknown. This warrants careful serotype-specific sur-
veillance of the effect of vaccination on both pneumococcal
carriage and invasive disease, rather than the discontinuation
of vaccination. Fortunately, data on the effect of broad-scale
vaccination on the pneumococcal serotypes causing invasive
disease are rapidly accumulating in the United States, where
the pneumococcal conjugate vaccine is now in wide use.
TERHI KILPI, M.D.
JUHANI ESKOLA, M.D.
P. HELENA MÄKELÄ, M.D.
National Public Health Institute
FIN-00300 Helsinki, Finland
FOR THE FINNISH OTITIS MEDIA STUDY GROUP
Editor’s note: Dr. Eskola has been an employee of Aventis
Pasteur since the beginning of 2000. Drs. Eskola and Kilpi
have served as consultants to Wyeth Lederle Vaccines.
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JAMA 2000;283:1460-8.
2. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunoge-
nicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr 
Infect Dis J 2000;19:187-95.
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The Effect of Risedronate on the Risk 
of Hip Fracture in Elderly Women
To the Editor: The report by McClung et al. (Feb. 1 is-
sue)1 is unconvincing, because information is not present-
ed to show that the women in the treatment and placebo
groups had similar clinical risk factors for hip fracture. This
information should have been included in the table show-
ing the base-line characteristics of the groups.
PAUL C. ROYCE, M.D., PH.D.
9 Prospect Rd.
Atlantic Highlands, NJ 07716
1. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the 
risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40.
To the Editor: McClung et al. state that “complete fol-
low-up data were available for 64 percent of the women.”
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In other words, follow-up data were incomplete for 36 per-
cent, or 3324, of the 9331 women. One wonders how to
interpret an estimated overall absolute difference in the inci-
dence of hip fracture of 1.1 percentage points, or 42 women
with fractures, in the light of such incomplete data. A slight
preponderance of fractures among those lost to follow-up in
the risedronate group could render the results inconclusive.
ROBERT L. GOODMAN, M.D.
Columbia University College of Physicians and Surgeons
New York, NY 10032
To the Editor: McClung et al. found that risedronate in
addition to calcium and vitamin D reduced the risk of hip
fracture in women 70 to 79 years old who were recruited
on the basis of a low bone mineral density at the femoral
neck. This suggests that screening for low bone mineral den-
sity followed by an appropriate treatment may be worth-
while even in elderly women, as long as they have a very low
bone mineral density. To assess whether the incidence of
hip fracture continues to rise when the bone mineral den-
sity decreases to very low values, even in very elderly wom-
en, we reanalyzed the data from a prospective cohort study
of 7598 women 75 years old or older (the Epidémiologie
de l’Ostéoporose [EPIDOS] study).1,2 The age-adjusted
incidence of hip fracture increased from 5.7 per 1000 per-
son-years among women with a T score of –2.5 or lower to
36.5 per 1000 person-years among women with a T score
lower than ¡4. In the trial of risedronate conducted by
McClung et al., no effect was observed among the women
80 years old or older. However, most women in this sub-
group were enrolled on the basis of clinical risk factors only,
and many did not have very low bone mineral density. In
the EPIDOS study, among 4478 women 80 years old or
older, 77 percent had one or more clinical risk factors.3 Of
these, only 27 percent had a T score below –3. These results
emphasize the need to measure bone mineral density at
the femoral neck to identify elderly women in whom ther-
apy to prevent fracture is appropriate.
ANNE-MARIE SCHOTT, M.D.
E. Herriot Hospital
69437 Lyons CEDEX 03, France
PATRICIA DARGENT-MOLINA, PH.D.
National Institute for Medical Research
94807 Villejuif CEDEX, France
PIERRE J. MEUNIER, M.D.
E. Herriot Hospital
69437 Lyons CEDEX 03, France
1. Schott AM, Cormier C, Hans D, et al. How hip and whole-body bone 
mineral density predict hip fracture in elderly women: the EPIDOS Pro-
spective Study. Osteoporos Int 1998;8:247-54.
2. Mazess RB, Barden H. Bone density of the spine and femur in adult 
white females. Calcif Tissue Int 1999;65:91-9.
3. Dargent-Molina P, Favier F, Grandjean H, et al. Fall-related factors and 
risk of hip fracture: the EPIDOS prospective study. Lancet 1996;348:145-
9. [Erratum, Lancet 1996;348:416.]
Dr. McClung replies:
To the Editor: Dr. Royce raises an important point. The
proportions of both the older and younger women with
various risk factors were balanced among the treatment
groups, so the observed treatment effect was not the result
of differences in risk at base line. Dr. Goodman expresses
appropriate concern about the potential effect of the in-
complete follow-up of the elderly women in our study. The
demographic characteristics with respect to the risk of frac-
ture were very similar between the women for whom we
had complete follow-up data and those for whom we did
not. Using the observed incidence of hip fractures that oc-
curred during follow-up, Dr. Goodman estimates that an
additional 42 hip fractures would have been observed if all
the women had been followed for three years. If we make
the conservative assumption that there is no treatment ef-
fect in these women, these fractures would be proportion-
ally distributed between the treatment groups, with 14 in
the placebo group and 28 in the risedronate group. In this
case, the reduction in the risk of hip fracture in the com-
bined risedronate groups would have remained significant
(risk reduction, 24 percent; 95 percent confidence inter-
val, 3 percent to 41 percent; P=0.03).
The information provided by Dr. Schott and colleagues
from their large observational study supports our findings
that elderly women with fall-related risk factors do not nec-
essarily have low bone density and may not be candidates for
drug therapy to reduce the risk of hip fracture. Although
bone mass decreases with advancing age, we cannot assume
that all older women have osteoporosis.
MICHAEL MCCLUNG, M.D.
Oregon Osteoporosis Center
Portland, OR 97213
Treatment of Calcium-Channel–Blocker 
Intoxication with Insulin Infusion
To the Editor: Overdose of calcium-channel blockers re-
mains an important cause of fatal poisoning.1 Convention-
al therapy, consisting of intravenous fluids, calcium, dopa-
mine, dobutamine, norepinephrine, and glucagon, often
fails to improve hemodynamic function in intoxicated pa-
tients.2 Recent recommendations for treatment of intoxi-
cation with calcium-channel blockers include induction of
hyperinsulinemia and euglycemia as adjunctive therapy.3 We
report two cases of overdose of calcium-channel blockers
in which a striking benefit was achieved with hyperinsuli-
nemia–euglycemia therapy.
A 34-year-old nondiabetic woman with hypertension
and renal failure ingested 12 extended-release tablets con-
taining 2.5 mg of amlodipine each. Hypotension and brad-
ycardia developed. Because of her history of renal failure, the
treating physicians did not administer calcium and instead
provided intravenous fluids, vasopressors, and glucagon.
A 48-year-old nondiabetic man with hypertension, chron-
ic obstructive pulmonary disease, congestive heart failure,
and depression was witnessed ingesting an unknown
amount of extended-release diltiazem. He became hemo-
dynamically unstable in the emergency department and
did not respond to calcium, intravenous fluids, and vaso-
pressors.
When conventional therapy failed to improve the hemo-
dynamic status of these patients, hyperinsulinemia–eugly-
cemia therapy with a continuous infusion of insulin at a rate
of 0.5 IU per kilogram of body weight per hour rapidly
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reversed cardiovascular collapse in both. Despite the high
doses of insulin administered, the first patient required no
supplemental glucose, whereas the second received 10 per-
cent dextrose at 100 ml per hour to maintain an average
serum glucose concentration of 140 mg per deciliter. The
clinical courses of the two patients are outlined in Table 1.
The clinical features of toxicity from calcium-channel
blockers arise from blockade of L-type calcium channels in
myocardial cells, smooth-muscle cells, and beta cells.4 An-
tagonism of these channels produces bradycardia, conduc-
tion delay, peripheral vasodilation, hypoinsulinemia, hyper-
glycemia, metabolic acidosis, and shock. Hypoinsulinemia
may be a critical factor in overdose of calcium-channel block-
ers.5 In an unstressed state, myocytes oxidize free fatty acids
for metabolic energy.3,4 In a state of shock, such as that as-
sociated with overdose of calcium-channel blockers, myo-
cytes use glucose for fuel.3,4 Hypoinsulinemia may prevent
the uptake of glucose by myocytes, causing a loss of inotro-
py, decreased peripheral vascular resistance, and shock.3
The exact mechanism of action of hyperinsulinemia–
euglycemia therapy is poorly defined. Hyperinsulinemia–
euglycemia therapy improves inotropy and peripheral vas-
cular resistance and reverses acidosis, possibly by improving
the uptake of carbohydrates by myocytes and smooth-mus-
cle cells.3,4 Although hypoglycemia may occur with this
therapy, the ease with which serum glucose can be meas-
ured by bedside capillary testing minimizes the likelihood
of this complication. As other case reports have suggested,
hyperinsulinemia–euglycemia therapy is safe and effective
for life-threatening overdose of calcium-channel blockers.3
EDWARD W. BOYER, M.D., PH.D.
MICHAEL SHANNON, M.D., M.P.H.
Children’s Hospital
Boston, MA 02155
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TABLE 1. CLINICAL COURSES OF TWO PATIENTS TREATED WITH HYPERINSULINEMIA–EUGLYCEMIA THERAPY.
PATIENT
NO.
VITAL SIGNS
BEFORE THERAPY
SERUM GLUCOSE
CONCENTRATION
BEFORE THERAPY
CONVENTIONAL THERAPY
ATTEMPTED
VITAL SIGNS
AFTER
THERAPY
RATE OF
INSULIN
INFUSION
TIME FROM INSULIN
INFUSION TO
DISCONTINUATION 
OF OTHER 
VASOACTIVE DRIPS
VITAL SIGNS 
AFTER INSULIN 
INFUSION 
ALONE
DURATION 
OF INSULIN 
DRIP
SUPPLEMENTAL 
GLUCOSE 
ADMINISTERED
mg/dl IU/kg/hr min hr
1 Pulse, 60; 
blood pressure, 
40 mm Hg
by palpation; 
afebrile
325 4 liters of intravenous fluids; 
20 µg/kg/min of dopa-
mine; 10 µg/kg/min of 
dobutamine; 14 µg/kg/min 
of norepinephrine; 5 mg 
of intravenous glucagon
Unchanged 0.5 45 Pulse, 100; 
blood 
pressure, 
150/60 
mm Hg
6 None
2 Pulse, 68; 
blood pressure, 
60/40 mm Hg; 
afebrile
170 2 liters of intravenous fluids;
4 g of calcium gluconate; 
20 µg/kg/min of dopa-
mine; 10 µg/kg/min of 
dobutamine
Unchanged 0.5 30 Pulse, 65; 
blood 
pressure, 
115/60 
mm Hg
6 100 ml/hr 
of 10% 
dextrose
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